Acadia Pharmaceuticals (NASDAQ: ACAD) revenue
Acadia Pharmaceuticals reported revenue of $1,072m for fiscal 2025, 11.9% more than in fiscal 2024 ($957.8m). Since fiscal 2016 its revenue has grown by 6,082.6%, an average growth of 58.1% a year.
Acadia Pharmaceuticals has grown its revenue for 9 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,072m | +11.9% | $104.8m | 9.8% |
| 2024 | $957.8m | +31.8% | $230.8m | 24.1% |
| 2023 | $726.4m | +40.4% | −$73.4m | −10.1% |
| 2022 | $517.2m | +6.8% | −$223.6m | −43.2% |
| 2021 | $484.1m | +9.6% | −$170.4m | −35.2% |
| 2020 | $441.8m | +30.3% | −$286.6m | −64.9% |
| 2019 | $339.1m | +51.5% | −$246.5m | −72.7% |
| 2018 | $223.8m | +79.2% | −$247.4m | −110.6% |
| 2017 | $124.9m | +620.7% | −$292.4m | −234.1% |
| 2016 | $17.3m | — | −$272.8m | −1,574.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Acadia Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Acadia Pharmaceuticals ranks 147th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Acadia Pharmaceuticals, 11.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 145th | Prestige Consumer Healthcare | $1,089m | −4.3% |
| 146th | Embecta | $1,080m | −3.8% |
| 147th | Acadia Pharmaceuticals | $1,072m | 11.9% |
| 148th | Tandem Diabetes Care | $1,015m | 7.9% |
| 149th | InnovAge | $989.7m | 15.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Acadia Pharmaceuticals
- How much revenue did Acadia Pharmaceuticals make in fiscal 2025?
- Acadia Pharmaceuticals reported revenue of $1,072m for fiscal 2025, compared with $957.8m in fiscal 2024.
- How much has the revenue of Acadia Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $17.3m to $1,072m: 6,082.6% more, an average growth of 58.1% a year.
- What was the best year for revenue at Acadia Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $1,072m.
- Where does Acadia Pharmaceuticals rank in its sector by revenue?
- It ranks 147th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Acadia Pharmaceuticals come from?
- From the annual report (Form 10-K) that Acadia Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Acadia Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Acadia Pharmaceuticals: the Acadia Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.